Liquidia Co. (NASDAQ:LQDA) Insider Sells $28,265.94 in Stock

Liquidia Co. (NASDAQ:LQDA) insider Rajeev Saggar sold 2,526 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $11.19, for a total transaction of $28,265.94. Following the completion of the transaction, the insider now directly owns 204,857 shares of the company’s stock, valued at $2,292,349.83. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Rajeev Saggar also recently made the following trade(s):

• On Monday, October 14th, Rajeev Saggar sold 2,260 shares of Liquidia stock. The stock was sold at an average price of $11.11, for a total transaction of $25,108.60.

Liquidia Price Performance

NASDAQ LQDA opened at $11.05 on Friday. Liquidia Co. has a 1-year low of $6.06 and a 1-year high of $16.99. The firm has a market capitalization of $844.37 million, a P/E ratio of -7.08 and a beta of 0.22. The business’s 50-day simple moving average is $10.24 and its 200-day simple moving average is $11.82.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. The business had revenue of $3.66 million during the quarter, compared to analysts’ expectations of $7.92 million. On average, equities research analysts expect that Liquidia Co. will post -1.69 EPS for the current fiscal year.

Analysts Set New Price Targets

LQDA has been the topic of a number of analyst reports. Lifesci Capital assumed coverage on shares of Liquidia in a research report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 target price on the stock. Needham & Company LLC restated a “buy” rating and set a $25.00 price objective on shares of Liquidia in a report on Monday, August 19th. Raymond James upgraded Liquidia from an “outperform” rating to a “strong-buy” rating in a research note on Monday, August 19th. HC Wainwright decreased their price target on Liquidia from $32.00 to $29.00 and set a “buy” rating on the stock in a research note on Tuesday, August 20th. Finally, Bank of America dropped their price objective on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, August 20th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $24.67.

Hedge Funds Weigh In On Liquidia

Several hedge funds and other institutional investors have recently made changes to their positions in LQDA. Quest Partners LLC purchased a new position in Liquidia in the second quarter valued at about $27,000. Hilltop National Bank acquired a new stake in shares of Liquidia in the second quarter valued at about $33,000. Clear Harbor Asset Management LLC acquired a new stake in shares of Liquidia in the third quarter valued at about $100,000. Signaturefd LLC raised its holdings in shares of Liquidia by 38,400.0% during the 3rd quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock valued at $100,000 after buying an additional 9,984 shares during the period. Finally, Ballentine Partners LLC acquired a new position in Liquidia during the 3rd quarter worth approximately $110,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).